Encrypted optical markers for security applications

Information

  • Patent Grant
  • 10745825
  • Patent Number
    10,745,825
  • Date Filed
    Thursday, July 5, 2018
    5 years ago
  • Date Issued
    Tuesday, August 18, 2020
    3 years ago
Abstract
Encrypted markers that are not readily detectable can be revealed by treatment with a specific reagent used as a developer to reveal a readily detectable physical property of the marker, such as a characteristic fluorescence emission after excitation with a particular excitation wavelength, or to reveal a visible color. The encrypted marker can be developed in situ, or a sample can be removed by brushing, scraping, swabbing or scratching the marked object or item and developing the encrypted marker or a sample thereof with the appropriate developer to reveal an overt marker or optical signal. The encrypted marker may include a DNA taggant.
Description
BACKGROUND

Fluorescent markers are useful as identification and security markers, but the advantage of their being readily visualized by irradiating with light of the appropriate excitation wavelength is also a disadvantage in that the fluorescent marker can be easily detected, analyzed and copied, rendering them subject to counterfeiting.


SUMMARY

The present invention provides encrypted markers that are not readily detectable, but can be revealed by treatment with a specific reagent used as a developer to reveal a readily detectable physical property of the marker, such as, for instance a characteristic fluorescence emission after excitation with a particular excitation wavelength, or to reveal a visible color. The encrypted marker can be developed in situ, or a sample can be removed by brushing, scraping, or scratching the marked object or item and developing the encrypted marker or a sample thereof with the appropriate developer to reveal an overt marker or optical signal. The marker can be revealed by exposure of the encrypted marker in situ or a sample thereof to the developer in solution, a spray, a vapor or a solid, such as for example, a powder or granules that include the developer. The marker may include a DNA taggant encoding information about the marked item.


Alternatively, there may be sufficient transfer of the encrypted marker molecules from the marked object or item by simply swiping with a swab carrying the developer, e.g. a swab soaked in a solution of the developer or a swab on which the developer is bound or covalently immobilized. The transferred encrypted marker molecules are then developed on or in the swab, or on the marked object or item. The swab, or the marked object or item, can be readily inspected for the presence of the revealed optical characteristics, such as color or fluorescence with emission at a specific wavelength after excitation with the appropriate wavelength of light.


The developer can be a chemically reactive developer that reacts with the marker to produce a detectable marker product, or the developer can be a chelating agent or other binding agent that in combination with the marker produces a detectable marker product. In another embodiment, the developer can be an ion, such as for instance, a metal ion that is bound by the marker to produce a detectable marker product.


In one embodiment, the marker of the present invention is an “encrypted fluorophore” (also referred to herein as a “pro-fluorophore”) and does not have the properties of a fluorophore and is thus difficult to recognize as a security marker, but on development or reaction with a developer, which is a specific reagent suitable for development of the pro-fluorophore, is transformed into a fluorophore with a readily detectable signal. Additionally, encryption often improves the physical and chemical stability of the pro-fluorophore.


In another embodiment, the chromogenic markers (also referred to herein as “chromogens” or “pro-chromophores”) of the present invention are “encrypted chromophores” and are colorless or almost colorless, and are thus difficult to recognize as security markers, but on development or reaction with a developer, a specific reagent, are transformed into a readily detectable chromophore. In one embodiment, the chromophores of the invention are made visible to the naked eye after development of the respective chromogenic markers with the developer reagent specific to the chromogenic marker.


In another embodiment, the markers of the present invention combine the features of both encrypted fluorophores and encrypted chromophores, wherein the encrypted fluorophores are non-fluorescent or essentially non-fluorescent and the encrypted chromophores are colorless or essentially colorless, making them difficult to detect or recognize as security markers. However, on development or reaction with a developer, these encrypted markers are transformed into a readily detectable fluorophore and a readily detectable chromophore. In one embodiment, such a combination marker can be simultaneously interrogated for fluorescence with UV light of an appropriate excitation wavelength, as well as for color visible to the naked eye by visual inspection of the illuminated marker after development with an appropriate developer.


In another embodiment, the pro-fluorophore, chromogenic compound, or combination thereof may be combined with DNA suspended in an aqueous or non-aqueous solvent to form a DNA security marker. Preferably, the DNA is a taggant that is double-stranded DNA of a non-naturally occurring sequence that may be readily identifiable. The DNA security marker may also contain a perturbant to assist in recovery of the DNA and/or to physically separate the DNA from the pro-fluorophore and/or chromogenic compounds. The perturbant may be selected from the group consisting of a polyol or a diol or glycol, a starch or a pyrrolidone or a water immiscible compound. A preferred perturbant is polyethylene glycol.


Therefore, in one embodiment, the invention relates to a method for cryptically marking an item, the method including providing a marker wherein the marker is a pro-fluorophore, a chromogen, or a combination thereof being capable of producing a readily detectable fluorophore, chromophore, or combination thereof upon reaction with a developer, and combining the DNA taggant and the marker to form a DNA security marker; attaching the DNA security marker to the item; and thereby providing a cryptically marked item.


In one embodiment, the inventive concept provides a method for cryptically marking an item, wherein the method includes: providing a chromogenic compound as a marker capable of producing a chromophore upon reaction with a developer, and (i) coating the item with a coating comprising the chromogenic marker compound; (ii) attaching a label or indicia comprising the chromogenic marker compound to the item; or (iii) embedding the chromogenic marker compound in at least a portion of the item; and thereby providing a cryptically marked item.


In another embodiment, the inventive concept provides a method for cryptically marking an item, wherein the method includes: providing a pro-fluorophore (also referred to as a cryptic fluorophore) capable of producing a fluorescent compound upon reaction with a developer, and (i) coating the item with a coating comprising the pro-fluorophore; (ii) attaching a label or indicia comprising the pro-fluorophore to the item; or (iii) embedding the pro-fluorophore in at least a portion of the item; and thereby providing a cryptically marked item.


In one embodiment of the inventive concept, a pro-fluorophore or chromogenic compound is used as a marker on an object to be tracked or authenticated. The marker may be painted, printed, sprayed, bonded, affixed to or embedded in or on the object or item of interest.


The item of interest may be swiped, rubbed or treated with a swab soaked in a solution of a developer, which is a specific reagent, capable of transforming the encrypted fluorophore marker or chromogenic marker compound into a fluorophore or chromophore, respectively, with a readily detectable signal. In one embodiment, the developer may be immobilized on the swab, e.g. by adsorption or by covalent bonding. Alternatively, the item of interest may be directly exposed to the developer in the form of a vapor, a spray or a solution. The development and authentication of the encrypted fluorophore marker or chromogenic marker compound can be performed by any suitable method, such as for instance and without limitation, in a single step wherein the encrypted fluorophore marker or chromogenic marker compound is developed directly in situ in or on the marked object, or in a two-step procedure, wherein the marker is first transferred to a sampling device or swab etc., and then treated with an appropriate developer delivered in the form of a vapor, a spray or a solution, or by sprinkling the sampling device or swab etc. with a powder or granules consisting of or containing the developer.







DETAILED DESCRIPTION
Definitions

Alkyl, as used herein, refers to a saturated branched or straight chain monovalent hydrocarbon radical of a specified number of carbon atoms. Thus, the term alkyl includes, but is not limited to, methyl (C1 alkyl), ethyl (C2 alkyl), propyl (C3 alkyl), isopropyl (also C3 alkyl), n-butyl(C4 alkyl), isobutyl (also C4 alkyl), sec-butyl (also C4 alkyl), and t-butyl (also C4 alkyl).


Alkenyl refers to branched or straight chain hydrocarbon radical having at least one double bond between two carbon atoms.


Alkynyl refers to branched or straight chain hydrocarbon radical having at least one triple bond between two carbon atoms.


Cycloalkyl as used herein means a saturated monocyclic, polycyclic or bridged hydrocarbon ring system substituent or linking group. In a substituted cycloalkyl ring, the substituent is bonded to ring carbon atom replacing a hydrogen atom. For example, C3-C10 cycloalkyl designates a ring of three to ten carbon atoms, or a ring of three or more carbon atoms wherein the remaining carbon atoms forming one or more alkyl substituents of the ring.


Heterocyclyl as used herein means a saturated, partially unsaturated or unsaturated monocyclic, polycyclic or bridged hydrocarbon ring system substituent or linking group, wherein at least one ring carbon atom has been replaced with a heteroatom such as, but not limited to nitrogen, oxygen, sulfur, selenium, boron or phosphorus. A heterocyclyl ring system can be a ring system having one, two, three or four nitrogen ring atoms, or a ring system having zero, one, two or three nitrogen ring atoms and one oxygen or sulfur ring atom. The heterocyclic ring system can include more than one ring heteroatom. A heterocyclyl substituent is derived by the removal of one hydrogen atom from a single carbon or nitrogen ring atom. Heterocyclyl includes, but is not limited to, furyl, thienyl, 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, pyrrolyl, 1,3-dioxolanyl, oxazolyl, thiazolyl, imidazolyl, 2-imidazolinyl, imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, tetrazolyl, 2H-pyranyl, 4H-pyranyl, pyridinyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, azepanyl, diazepinyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thienyl, 1H-indazolyl, benzimidazolyl, benzothiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalzinyl, quinazolinyl, quinoxalinyl, 1,8-napthyridinyl, pteridinyl, quinuclidinyl.


As noted above, heterocyclyl also includes aromatic heterocycles, such as pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furyl, thienyl, pyridyl, pyrazinyl, pyrimidinyl, and can be optionally substituted, for instance with alkyl. Heterocyclyl also includes bicyclic heterocyclyls with one or both rings having a heteroatom, e.g. imidazopyrazinyl, benzofuranyl, benzodioxolyl, benzothiophenyl, and quinolinyl.


Arylalkyl means an aryl group attached to the end carbon atom of an alkyl group such as, for instance C1-C4 alkyl.


Aryl means an aromatic, unsaturated pi-electron conjugated monocyclic or polycyclic hydrocarbon ring system substituent or linking group of six, eight, ten or fourteen carbon atoms. An aryl group is derived by the removal of one hydrogen atom from a carbon ring atom. Aryl includes, but is not limited to, phenyl, naphthalenyl, azulenyl and anthracenyl.


Halo—means fluoro (—F), chloro (—Cl), bromo (—Br) or iodo (—I).


Carboxyl means a substituent of the formula —COOH.


Hydroxyl means a substituent of the formula —OH.


Cyano means a substituent of the formula —C≡N.


Nitro means a substituent of the formula —NO2.


Oxo means a substituent of the formula ═O in which the oxygen atom is double bonded. Amino means a substituent of formula —NH2 or a linking group having the formula —NH—. Alkylamino or dialkylamino means a substituent of the formula —NH-alkyl or —N(alkyl)2, respectively.


Azido means a substituent of the formula —N3 also represented as —N═N±═N.


Attaching a security marker to an item includes all means of putting the two together including affixing, embedding, coating, painting, printing, spraying, bonding, and combinations thereof.


Compounds useful in the practice of the present invention as marker pro-fluorophores or chromogenic compounds include pro-fluorophore forms of xanthane dyes such as rhodamines, rhodols and fluoresceins, as well as derivatives of coumarin, cyanine and oxazine. The marker is defined as a pro-fluorophore, chromogen, or combination thereof.


The marker may be combined with DNA suspended in an aqueous or non-aqueous solvent to form a DNA security marker. The DNA is preferably a taggant. In one example, the DNA taggant is a double stranded DNA molecule having a length of between about 20 base pairs and about 1000 base pairs. In another example, the DNA taggant is a double-stranded DNA molecule with a length of between about 80 and 500 base pairs. In another example, the DNA taggant is a double-stranded DNA molecule having a length of between about 100 and about 250 base pairs. Alternatively, the DNA taggant can be single-stranded DNA of any suitable length, such as between about 20 bases and about 1000 bases; between about 80 bases and 500 bases; or between about 100 bases and about 250 bases. The DNA taggant can be a naturally-occurring DNA sequence, whether isolated from natural sources or synthetic; or the DNA taggant can be a non-naturally occurring sequence produced from natural or synthetic sources. All or a portion of the DNA may comprise an identifiable sequence. The preferred DNA is double-stranded DNA of a non-naturally occurring sequence.


Preferably, the DNA taggant is identifiable by any suitable nucleic acid amplification and/or taggant sequence detection technique. Nucleic acid amplification may be accomplished via any technique known in the art, such as, for example, polymerase chain reaction (PCR), loop mediated isothermal amplification, rolling circle amplification, nucleic acid sequence base amplification, ligase chain reaction, or recombinase polymerase amplification. In addition, any known sequence detection and/or identification technique may be used to detect the presence of the nucleic acid taggant such as, for example, hybridization with a taggant-sequence specific nucleic acid probe, an in situ hybridization method (including fluorescence in situ hybridization: FISH), as well as amplification and detection via PCR, such as quantitative (qPCR)/real time PCR (RT-PCR). Isothermal amplification and taggant sequence detection may also be performed with the aid of an in-field detection device such as the T-16 Isothermal Device manufactured by TwistDX, Limited (Hertfordshire, United Kingdom).


The pro-fluorophores, chromogens, or combination thereof (the marker) are present in a large excess weight by weight (w/w) relative to the DNA taggant. The w/w ratio of DNA taggant to pro-fluorophores, chromogens, or combination thereof may be from about 1:100 to about 1-10,000. The preferable w/w ratio is about 1:800 to 1:5,000.


Additionally, to assist in the recovery of the DNA taggant and/or to create a physical separation between the pro-fluorophores, chromogenic compounds, or combination thereof, and the DNA taggant, a perturbant may be included with the DNA. Examples of perturbants include, but are not limited to, a polyol or a diol or glycol, a starch or a pyrrolidone. The polyol can be any suitable polyol, such as a polyethylene glycol polymer, for instance a PEG 200 i.e. a polyethylene glycol having an average molecular number of 200 ethylene glycol units per chain (such as the PEG200 Mn 200 Product No. P3015, Sigma-Aldrich, St. Louis, Mo.). Alternatively, in another embodiment, the polyethylene glycol can be a PEG 10,000 polyol polymer (such as the PEG10,000 Product No. P3015, Mn 10,000 from Sigma-Aldrich).


Examples of glycols include, but are not limited to, any suitable glycol or diol, such as for instance, ethylene glycol, diethylene glycol, glycerol, methanediol, triethylene glycol, propylene glycol from Sigma-Aldrich, or 1,2-butanediol or 1,4-butanediol from Fluka Analytical. Examples of starches include, but are not limited to, a hydroxypropyl starch such as Zeina® B860 from Grain Processing Corp., Muscatine, Iowa. Pyrrolidones include, but are not limited to, an N-alkyl pyrrolidone, or the caprylyl pyrrolidone surfactant: Surfadone® LP100 available from Ashland Inc., Covington, Ky.


Perturbants may also include any water immiscible compound capable of creating a stable oil-in-water emulsion. Examples of such compounds include mineral oil, hydrocarbons, silicone oils and triglycerides. Prior to incorporation with the pro-fluorophores and/or chromogenic compounds, DNA suspended in an aqueous solution may be mixed with a perturbant to form a stable emulsion.


Preferably the perturbant is present in a composition including the DNA taggant and the pro-fluorophores, chromogenic compounds, or combination in an amount less than 2% w/w of the total composition including the DNA taggant; pro-fluorophores, chromogenic compounds, or combinations thereof; and the perturbant (i.e., w/w of the DNA security marker). Any of the following percentages may be used to represent the value or may be combined to represent a range of values or minima or maxima for the amount of perturbant in the total composition: 2%, 1.5%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, and 0.01%. The perturbant may also be present in a composition including the DNA taggant and the pro-fluorophores, chromogenic compounds, or combination thereof in amount in about 50% to about 80% w/w excess of DNA suspended in an aqueous solution to form a DNA/perturbant emulsion. The DNA/perturbant emulsion is then added to the pro-fluorophores and/or chromogenic compounds.


Scheme I shows the general case of a profluorophore (Pro-FL) also interchangebly referred to herein as a fluorogenic compound, treated with a developer to produce a fluorescent compound (FL*) having a characteristic emission wavelength when stimulated with light of the appropriate excitation wavelength, wherein the emitted light is readily detectable either by eye or by spectroscopic measurement.




embedded image


Scheme II shows the general case of a chromogenic compound (CHR-gen) also interchangebly referred to herein as a leuco-form of a chromophore (i.e. a chromogen) treated with a developer to produce a chromophore or dye (CHR*) having a characteristic absorption that is readily detectable either by eye or by spectroscopic measurement.




embedded image


Examples of fluorescein derivatives useful in the practice of the present invention as marker pro-fluorophores or chromogenic compounds are derivatives of each of the following compounds: Fluorescein, 5-(and-6-)-Carboxyfluorescein (FAM), 5-(and-6)-4,7,2′,7′-Tetrachlorofluorescein (TET), 5-(and-6)-2′,4′,4,5′,7′,7-hexachlorofluorescein (HEX), 5-(and-6)-Carboxy-4′,5′-Dichloro-2′,7′-Dimethoxyfluorescein (JOE), Eosin Y (2′,4′,5′,7′-Tetrabromofluorescein), Eosin B (4′,5′-Dibromo-2′,7′-dinitrofluorescein), Rose Bengal (4,5,6,7-Tetrachloro-2′,4′,5′,7′-tetraiodofluorescein), Erythrosin (2′,4′,5′,7′-Tetraiodofluorescein), 2,7-Dichlorofluorescein, Yakima Yellow, VIC, NED, and many more well known to those of skill in the art of fluorescent compounds and dyes. These derivatives are generally colorless, or essentially colorless and lack appreciable fluorescence; and can be treated with a suitable developer to produce the fluorescent compound or the dye itself.


Examples of rhodamines useful as marker pro-fluorophores or chromogenic compounds include for instance: derivatives of Tetramethylrhodamine (TRITC), 5-(and-6)-Carboxytetramethylrhodamine (TAMRA), 5-(and-6)-carboxy-X-rhodamine (ROX), Rhodamine 110 (Xanthylium, 3,6-diamino-9-(2-carboxyphenyl)-, salts), Rhodamine B, Rhodamine 6G, etc.


Examples of oxazines useful as marker pro-fluorophores or chromogenic compounds include derivatives of: Nile Red, Nile Blue, Cresyl Violet and Oxazine 170, etc., which can be treated with a developer to reveal the underivatized Nile Red, Nile Blue, Cresyl Violet or Oxazine 170 marker.


For instance, in one embodiment, the pro-fluorophore can be a xanthane, such as for instance:




embedded image



wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from hydrogen, halogen (F, Cl, Br, I), nitro (NO2), cyano (CN), carbonyl (CHO or C(O)R), C1-C8 alkyl, aryl, and C3-C8 cycloalkyl, each optionally substituted with one or more functional groups such as carboxyl, carbonyl, amino, cyano, nitro, alkyl, alkenyl, alkynyl or azido.


Alternatively, a pair of R groups independently selected from R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 can form a ring between one another or between Rn (one of R1-R10) and either X or Y or both; X and Y are substituted oxygen, X═OR or nitrogen, Y═NRR′ wherein substituents R and R′ independently selected from hydrogen, C1-C8 alkyl, aryl, C1-C8 acyl (each alkyl, aryl and acyl being optionally substituted with one to three substituents independenly selected from halo, nitro (NO2), and C1-C3 alkyl), alkylsulfonyl (RSO2—) and arylsulfonyl (ArSO2—), (wherein the alkylsulfonyl and arylsulfonyl are optionally substituted with one to three substituents independenly selected from halo, nitro (NO2), and C1-C3 alkyl), trialkyl and triarylsilyl; and Z represents oxygen (O), sulfur (S), selenium (Se) or substituted nitrogen (N—R″), wherein R″ is defined as for R above; or R″ is an amino group, NR′R′″, hydroxyl group or OR′″, wherein R′″ is independently selected from the options for R as defined above.


In one embodiment, the pro-fluorophore (Pro-FL) useful in the practice of the present invention can be prepared from the fluorophore (FL*) by chemical conversions, known in the art, and as depicted in the general Scheme III, as shown below.




embedded image


In another embodiment, the said chromogen (CHR-gen) can be prepared from the chromophore (CHR*) by chemical conversions, known in the art, and as depicted in the general Scheme IV, shown below.




embedded image


Examples of the above conversions of fluorogen to pro-fluorogen or chromophore to chromogen according to the present invention are depicted in Examples 1, 2 and 6 below.


In another embodiment, the pro-fluorophore can be an oxazine such as for instance:




embedded image



wherein R1, R2, R3, R4, R5 and R6 are hydrogen, halogen (F, Cl, Br, I), nitro (NO2), cyano (CN), carbonyl (CHO or C(O)R), C1-C8 alkyl, C3-C8 cycloalkyl or aryl. Each of R1, R2, R3, R4, R5 and R6 can also form an optionally substituted ring between one another or between Rn and either X or Y, or both. X and Y are substituted oxygen, X═OR or nitrogen, Y═NRR′ wherein substituents R, R′ are independently selected from hydrogen, C1-C8 alkyl, aryl and C1-C8 acyl, trialkyl and triarylsilyl; each alkyl, aryl and acyl being optionally substituted with one to three substituents independently selected from halo, nitro (NO2) and C1-C3 alkyl), alkylsulfonyl (RSO2—) and arylsulfonyl (ArSO2—), wherein the alkylsulfonyl and arylsulfonyl are each optionally substituted with one to three substituents independently selected from halo, nitro (NO2) and C1-C3 alkyl.


In another instance, in one embodiment, the pro-fluorophore can be a coumarin such as:




embedded image



wherein R1, R2, R3, R4 and R5 are each independently, hydrogen, halogen (F, Cl, Br, I), nitro (NO2), cyano (CN), carbonyl (CHO or C(O)R), C1-C8 alkyl, C3-C8 cycloalkyl, or aryl; wherein each alkyl, aryl and acyl is optionally substituted with one to three substituents independently selected from halo, nitro (NO2) and C1-C3 alkyl), alkylsulfonyl (RSO2—) and arylsulfonyl (ArSO2—), wherein the alkylsulfonyl and arylsulfonyl are each optionally substituted with one to three substituents independently selected from halo, nitro (NO2) and C1-C3 alkyl. R1, R2, R3, R4 and R5 can also form a ring between one another or between Rn and X; wherein X represents substituted oxygen, X═OR or substituted nitrogen, X═NRR′ wherein substituents R, R′ are independently hydrogen, alkyl, aryl, or C1-C8 acyl, (each alkyl, aryl and acyl being optionally substituted with one to three substituents independently selected from halo, nitro (NO2) and C1-C3 alkyl), alkylsulfonyl (RSO2—) and arylsulfonyl (ArSO2—), wherein the alkylsulfonyl and arylsulfonyl are optionally substituted with one to three substituents independently selected from halo, nitro (NO2), and C1-C3 alkyl groups; trialkyl and triarylsilyl, and Y represents either oxygen (O) or NH.


In another embodiment, the pro-fluorophore can be a compound of Formula IV, as shown below:




embedded image



wherein R1, R2, R3, R4 and R5 are each independently, hydrogen, halogen (F, Cl, Br, I), nitro (NO2), cyano (CN), C1-C8 alkyl, C3-C8 cycloalkyl, or aryl, each alkyl, cycloalkyl and aryl being optionally substituted with one to three substituents independently selected from halo, nitro (NO2), and C1-C3 alkyl. R1, R2, R3, R4 and R5 can also form a ring between any two of R1, R2, R3, R4 and R5, or between any one of R1, R2, R3, R4 and R5 and the N of Formula IV; and wherein R is hydrogen, C1-C8 alkyl, C3-C8 cycloalkyl, arylalkyl (such as benzyl), or aryl wherein each of the C1-C8 alkyl, C3-C8 cycloalkyl, arylalkyl and aryl are optionally substituted with one to six substituents independently selected from carboxyl (COOH), sulfonate (SO3H) and amino (NH2). X in Formula IV represents a counter-ion exemplified by but not limited to: chloride, bromide, iodide, tosylate, mesylate and perchlorate.


In another embodiment, the pro-fluorophore can be a compound of Formula V, as shown below:




embedded image



wherein R1, R2 and R3 are hydrogen, halogen (F, Cl, Br, I), nitro (NO2), C1-C8 alkyl, C3-C8 cycloalkyl, or aryl, each independently optionally substituted with one to three halo, nitro (NO2), C1-C3 alkyl groups. R1, R2 and R3 can also form a cyclic structure between any two of R1, R2 and R3, or between any one of R1, R2 and R3 and N or Y of the heterocycle of formula V; and wherein R is hydrogen, or C1-C8 alkyl, C3-C8 cycloalkyl, arylalkyl (such as benzyl), or aryl, each alkyl, cycloalkyl and arylalkyl being independently optionally substituted. Suitable substituents include but are not limited to carboxyl (COOH), sulfonate (SO3H), and amino (NH2) etc. X represents a suitable counter-ion such as for instance, but not limited to: chloride, bromide, iodide, tosylate, mesylate and perchlorate. Y is oxygen, nitrogen, sulfur, selenium or C(CH3)2.


In another embodiment of the invention, the pro-fluorophore can be any of the moieties A, L1, L2, L3, L4 in Formula VI (below):




embedded image


Wherein the sum of m+n+p+q is a positive integer between 1 and 12; m is at least one; and n, p and q are each independently zero or a positive integer. In one embodiment, the complex is formed from A, L1, L2, L3, L4 in Formula VI with or without the assistance of a catalyst or activator as explained below.


Furthermore, L1, L2, L3, L4 can each be different from each other (L1≠L2≠L3≠L4); or two or more of the moieties L1, L2, L3 and L4 can be the same. In one particular embodiment the moieties L1, L2, L3 and L4 are all the same (L1=L2=L3=L4).


The structure represented by Formula VI is a coordination compound such as, for instance, an organometallic compound, where A is a central ion which is chelated by ligands L1, L2, L3, L4. Central ion A and ligands L1, L2, L3, L4 are chosen in such a way that only the combination of A coordinated by ligands L1, L2, L3, L4 will generate a discreet spectroscopic signal manifested by color or fluorescence, or both.


L1, L2, L3, L4 can be any chemical moiety capable of forming coordination bonds with central ion A, via electron pairs available on a nitrogen, oxygen, sulfur or selenium atom of the ligand. One category of the molecules useful in the present invention as a ligand incorporates a heterocyclic compound and derivatives thereof, which may include, but is not limited to a heterocycle selected from: furane, thiophene, pyrrole, oxazole, thiazole, imidazole, pyrazolidinyl, pyrazole, isoxazole, isothiazole, oxadiazole, triazole, thiadiazole, tetrazole, 2H-pyrane, 4H-pyrane, pyridine, bipyridyl, terpyridine, triazine, piperidine, pyrrolidine, 1,4-dioxane, morpholine, 1,4-dithiane, thiomorpholine, pyrazine, pyridazine, pyrimidine, piperazole, azepane, diazepine, indolizine, indole, isoindole, benzimidazole, benzoxazole, benzothiazole, purine, quinolizidine, quinoline, isoquinoline, diazanaphthalenes, pteridine and phenanthroline.


Another category of the ligands L includes polydentate chelators and their derivatives, such as ethylenediaminetetraacetic acid (EDTA), 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA), diethylenetriaminepentaacetic acid (DTPA), triethylenetetramine-N,N,N′,N″, N′″,N″′-hexaacetic acid (TTHA), N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylene-diamine (TPEN), ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,8,11-tetraazacyclo-tetradecane-5,12-dione dehydrate (5,12-Dioxocyclam), calixarenes (e.g. meso-octamethyl-calix(4)pyrrole, calix[4]arene-25,26,27,28-tetrol, calix[6]arene), crown ethers (e.g. dibenzo-15-crown-5, cyclen), cyclodextrins (e.g. a-cyclodextrin).


Another category of ligands, L, includes but is not limited to β-diketones (e.g. acetylacetone and the derivatives thereof, including hexafluoroacetylacetone; 4,4,4-trifluoro-1-phenyl-1,3-butanedione; 1,3-diphenyl-1,3-propanedione); Phosphine oxides (e.g. triphenylphosphine oxide, n-trioctylphosphine oxide); aromatic acids and phenols and their derivatives (e.g. tiron, catechol, salicylic acid); Schiff bases and their derivatives (e.g. the 2-phenolsalicylimine depicted in Example 5 below).


Another class of ligands, L, includes solvent molecules. This class is chemically very diverse, and includes several of the compounds mentioned above, such as heterocyclic compounds (pyridine, collidine, furan, tetrahydrofurane (THF) etc.) and crown ethers (15-crown-5 etc.), as well as other molecules representing a broad selections of chemical functionalities. These include, for instance, the following molecules and their derivatives: water, alcohols (methanol, ethanol etc.), amines (triethylamine, diisopropylethylamine, morpholine, dimethylamine, N,N-dimethylaminopyridine (DMAP) etc.), ethers (diethyl ether etc.), polar aprotic solvents (dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), hexamethylphosphoramide (HMPA), 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), 1,3-dimethyl-2-imidazolidinone (DMI), 1-methyl-2-pyrrolidinone (NMP), acetonitrile (AcCN), sulfolane, tetraethylene glycol dimethyl ether (tetraglyme), etc.).


In embodiments of the present invention, central ion A can be any positively charged ion capable of forming a coordination compound with one or more of the ligands, L. One category of the ions, A useful in the practice of the present invention is the category of metal ions, including, but are not limited to, transition metal ions, alkaline and alkaline earth metal ions, lanthanides and actinides.


Central ion A can be provided in a form of an inorganic or organic salt. Suitable inorganic salts include, but are not limited to mineral acid salts such as, sulfates, sulfites, sulfides, nitrates, nitrites, carbonates, borates, phosphates, selenates, fluorides, chlorides, bromides, iodides, chlorates, perchlorates, etc. Suitable organic salts include, but are not limited to organic acid salts such as, monocarboxylic acid salts (e.g. salts of formic, acetic, propionic, butyric, pivalic, 2-ethylhexanoic, palmitic, stearic, oleic, benzoic, salicylic, 4-sulfosalicylic etc. acid), polycarboxylic acid salts (e.g. salts of oxalic, malonic, succinic, glutaric, adipic, citric, trimesic, mellitic etc. acids).


Another class of central ion A includes oxygen atom-containing moieties such as hydroxides and oxides etc.


The choice of the supplied form of central ion A for any particular embodiment of the present invention is dictated by the application (i.e. the object or item to be marked and its environment) and the carrier properties (i.e. the nature of the medium that includes the marker, such as for instance a coating, a paint or a varnish layer).


In one embodiment, the complex is formed from A, L1, L2, L3, L4 in Formula VI with the assistance of a catalyst or activator. The catalysts and activators useful in the practice of the present invention include basic and nucleophilic agents, exemplified but not limited to, simple organic and inorganic bases (hydroxides, amines, alkoxides, phenoxides and the like). This category also comprises inorganic or organic salts of weak acids and strong bases generating upon solvolysis alkaline solutions, e.g. ammonium, alkaline and alkaline earth metal carbonates, bicarbonates, borates, phosphates, acetates etc. Exemplary hydroxides are alkaline and alkaline earth hydroxides such as ammonium, lithium, sodium, potassium, rubidium, cesium, calcium, strontium or barium hydroxide as well as tetraalkylammonium hydroxides, such as tetramethylammonium or tetrabutylammonium hydroxide. Examples of amines useful as catalysts and activators include but are not limited to: triethylamine, diisopropylethylamine, benzylamine, morpholine, pyrrolidine, piperidine, dimethylaminoaniline etc. Examples of alkoxides and phenoxides useful as catalysts and activators include but are not limited to: alkaline alkoxides and phenoxides, such as: sodium or potassium methoxide, ethoxide or phenoxide.


In another embodiment, the catalyst is an acidic substance, as defined by either Bronsted-Lowry or Lewis theory, and can be represented by simple organic or inorganic acid, as well as any inorganic or organic salt of weak base and strong acid generating acidic conditions upon solvolysis, e.g. metal chloride, bromide, nitrate, sulfate etc.


Compounds useful as developers, i.e. decrypting agents in the practice of the present invention include compounds known in the art as good chelators or complexing agents, such as for instance and without limitation:

    • Heterocyclic aromatic compounds, e.g. imidazoles, phenanthrolines, pirydines, thiazoles and the derivatives thereof;
    • Polydentate chelators (EDTA, EGTA, BAPTA, DOTA, DTPA);
    • β-diketones (e.g. acetylacetone and the derivatives thereof, including but not limited to hexafluoroacetylacetone; 4,4,4-trifluoro-1-phenyl-1,3-butanedione; 1,3-diphenyl-1,3-propanedione);
    • Phosphine oxides (trioctylphosphine oxide; triphenylphosphine oxide);
    • Aromatic acids and polyphenols (e.g. salicylic acid, catechol, Tiron);
    • Aromatic aldehydes (e.g. 4-(N,N-dimethylamino)benzaldehyde, 4-(N,N-dimethylamino)cinnamaldehyde, p-anisaldehyde, 4-hydroxybenzaldehyde, etc.)
    • Schiff bases and derivatives (e.g. 2-phenolsalicyl imine depicted in Example 5 below).


Compounds useful as developers, i.e. decrypting agents in the practice of certain embodiments of the present invention include compounds known in the art as nucleophilic species, involved in solvolysis or deprotection, such as for instance, simple organic and inorganic bases (hydroxides, amines, alkoxides, phenoxides and the like); simple organic and inorganic salts (acetates, sulfides, iodides, fluorides, oxalates, citrates and the like).


Compounds useful as developers, i.e. decrypting agents in the practice of certain embodiments of the present invention also include compounds known in the art as acidic species, involved in solvolysis or deprotection such as simple organic and inorganic acids. In other embodiments, the developer can be an electrophilic species for solvolysis or deprotection, such as for instance, an aldehyde compound, e.g. benzaldehyde or salicyladehyde, or derivatives thereof.


In some specific embodiments the pro-fluorophore or chromogen can be used as the developer and any of the chemical compounds listed above can be used in the coating or embedded in the material marked. The chromogen or pro-fluorophore can then be used as the developer.


In some specific embodiments the developer may require the presence of the catalyst to speed up the decryption reaction of the encrypted fluorophore (which may also be referred to as a pro-fluorophore) or the encrypted chromophore (which may also be referred to as a prochromophore, or a chromogen) and to render the marker useful as a rapid in-field authentication system. The catalysts useful in the practice of the invention include for instance, basic and nucleophilic agents, exemplified but not limited to, simple organic and inorganic bases (hydroxides, amines, alkoxides, phenoxides and the like. In another embodiment, the catalysts can be a simple organic or inorganic acid.


EXAMPLES

1. Pro-Fluorophores


Encrypted pro-fluorophores are hidden/occult fluorophores that are revealed by development with a specific reagent that converts the pro-fluorophore or leuco-form that may be colorless and shows little or no fluorescence to the active fluorophore which may also be intensely colored under visible light.


For instance the compound, rhodamine B hydrazide, a colorless compound can be developed with Cu2+ metal ions under acidic conditions to yield a magenta compound with intense orange-red fluorescence. See the reaction illustrated above, showing the conversion of the colorless hydrazide to the magenta copper-coordinated compound by the copper ion, which in turn is slowly hydrolyzed to the colorless carboxylate.




embedded image


In other examples of profluorophores, the natural properties of susceptibility to a first order hydrolysis reaction can be used as a “time stamp” wherein the rate of decay in air or in a specific carrier under normal conditions is characteristic of the particular encrypted fluorophore. For example, the compound can be a leuco form chosen to be relatively stable in a liquid, such as an ink and decay over a period of weeks to produce a colored and intensely fluorescent form.


2. Two Part Fluorophores


The two part fluorophores are assembled from two non-fluorescent, or very weakly fluorescent components (A) and (B), in some cases in the presence of a catalyst. Only upon reaction of both (A) and (B) components is the actual fluorophore produced. The reaction between both components may also generate colorimetric changes in addition to developing fluorescence. Component (A) of the two part fluorophore can be used as the hidden security/authentication marker and the verification can be achieved by adding the second component (B) to component (A) to produce the active fluorophore. In certain embodiments this process may be enhanced by the addition of a catalyst.


For instance, substituted benzazolium salts can be used as the component (A) and developed with a specific reagent (and an optional catalyst) as exemplified below:


These non-fluorescent components (A) are stable and only revealed by exposure to the appropriate second components (B) and do not spontaneously decrypt over time.


Alternative substituents of the aromatic compounds can be used to change the spectral properties or solubility profile of the fluorophore at the option of the chemist or the designer of the pro-fluorophore as a cryptic marker.


3. Thermostable Pro-Fluorophores


Inorganic elements can be used as thermostable or even fire resistant markers that can be revealed by development with a specific reagent, which can be an organic component. For instance aluminum chloride (AlCl3) can be used as a covert marker that may be incorporated into for example an ink, a lacquer or a varnish and revealed by addition of a specific chelating agent which becomes intensely fluorescent by forming a coordination compound with new spectral properties. In some cases a catalyst may be required to speed the reaction. An example of the formation of an aluminum-based fluorophore from an aluminum chloride (AlCl3) marker is shown below:




embedded image


Other inorganic elements or ions useful as thermostable pro-fluorophores include anions such as phosphate ions, iodide ions, fluoride ions and acetate ions; and cations such as metal ions. Appropriate choice of alternative substituents of the aromatic coordination compounds or chemosensors can be used to change the spectral and other physicochemical properties of the fluorophore at the option of the designer.


4. Polymerizable Encrypted Pro-Fluorophores


Encrypted pro-fluorophores can be rendered polymerizable by addition of appropriate functional groups. Such encrypted pro-fluorophores can be based on excellent fluorophores (bright and with high quantum yields) that are readily and inexpensively synthesized. Pro-chromophores and pro-fluorophores with chromophoric and fluorescence emission properties can be provided, depending on the chromophore or fluorophore template chosen.




embedded image


The chemical stability and hydrophobicity of the pro-fluorophores can be controlled by choice of the appropriate acyl groups or aromatic ring substituents.


In one embodiment, the encrypted fluorophores can also be incorporated into nanoparticles containing DNA, such as for instance, and without limitation, lyophilized or encapsulated DNA. Polymerization of the above exemplified polymerizable pro-fluorophore in a methyl-methacrylate polymer is shown below:




embedded image


Such polymers can be used to encapsulate security markers, such as DNA or other biomolecules, or can be assembled as microparticles or nanoparticles for use as transferable markers, or for incorporation into polymers or other materials with or without entrapped DNA or other detectable marker(s).


The following examples 1-6 are embodiments of the above described compounds useful as encrypted optical markers of the invention.


Example 1: Synthesis of Rhodamine B Hydrazide



embedded image


Rhodamine B (479 mg) was dissolved in ethanol and excess of 65% aqueous hydrazine was added to this mixture under vigorous stiffing. After refluxing for 2 hours the reaction mixture was cooled and off-white precipitate was collected. The solid was extensively washed with ethanol:water mixture and the 2-amino-3′,6′-bis(diethylamino)spiro[isoindoline-3,9′-xanthene]-1-one product was dried in vacuo.


Example 2: Synthesis of Eosin Y Diacetate



embedded image


Eosin Y (648 mg) was suspended in acetic anhydride and the mixture was stirred at reflux for 5 hours. Then the reaction mixture was slowly added to ice-water mixture. The resulting light brown solid was collected and washed with several portion of water. Then the product was dissolved in dimethylformamide (DMF) and precipitated by adding to water. After water wash the solid-acetoxy-2′,4′,5′,7′-tetrabromo-3-oxo-spiro[isobenzofuran-1,9′-xanthene]-3′-yl) acetate product was dried in vacuo.


Example 3: Synthesis of 1,2-Dimethylbenzothiazolium iodide



embedded image


To 2-methylbenzothiazole (2.54 ml) in anhydrous toluene iodomethane (2.5 ml) was added in portions. The mixture was refluxed for 6 hours, cooled down to room temperature and then left for several hours at 4° C. Resulting yellow precipitate was collected and washed repeatedly with acetone. The solid 2,3-dimethyl-1,3-benzothiazole hydroiodide product was then dried in vacuo.


Example 4: Synthesis of a Fluorescent Dysprosium Complex



embedded image


4,4,4-Trifluoro-1-phenyl-1,3-butanedione (649 mg) and 1,10-phenanthroline were dissolved in absolute ethanol (3 ml). To this solution aqueous sodium hydroxide (1 M) was added dropwise and the reaction mixture was stirred for 10 min. Separately, dysprosium nitrate hydrate (456 mg) was dissolved in water (1 ml) and the solution was added to the alkaline dione. The reaction mixture was stirred at 60 C for 5 hours to give a white solid form of the dimethyl-dysprosium; methyl; RE)-[3-oxo-3-phenyl-1-(trifluoromethyl)propylidene]-3-oxidanyl]; 1,10-phenanthroline product.


Example 5: Synthesis of 2-Phenolsalicyl imine



embedded image


A solution of 2-hydroxyaniline (2.84 g) in ethanol was added to a solution containing 2-hydroxybenzaldehyde (3.4 g) in ethanol. The mixture was refluxed for 2 hours under nitrogen and then it was cooled to room temperature. The orange 2-[(E)-(2-hydroxyphenyl)iminomethyl]-phenol precipitate was washed with ice cold ethanol and dried in vacuo.


Example 6: Synthesis of Fluorescein Dimethacrylate



embedded image


Fluorescein sodium salt (376 mg) was suspended in methacrylic anhydride and the mixture was stirred at reflux for 5 hours. Then the reaction mixture was slowly added to ice-water mixture. Resulting light brown solid was collected and washed with several portion of water. Then the product was dissolved in dimethylformamide and precipitated by adding to water. After water wash the yellow solid 6′-(2-methylprop-2-enoyloxy)-3-oxo-spiro[isobenzofuran-1,9′-xanthene]-3′-y112-methylprop-2-enoate product was dried in vacuo.

Claims
  • 1. A method for cryptically marking an item, the method comprising: providing a marker wherein the marker is a pro-fluorophore, a chromogen, or a combination thereof being capable of producing a readily detectable fluorophore, chromophore, or combination thereof upon reaction with a developer, andcombining a DNA taggant and the marker to form a DNA security marker;attaching the DNA security marker to the item; andthereby providing a cryptically marked item.
  • 2. The method according to claim 1, wherein the marker is a pro-fluorophore.
  • 3. The method according to claim 1, wherein the marker is a chromogen.
  • 4. The method according to claim 1, wherein the DNA taggant is double-stranded DNA of a non-naturally occurring sequence that is readily identifiable.
  • 5. The method according to claim 1, wherein the DNA taggant has a length of between about 80 and 500 base pairs.
  • 6. The method according to claim 1, wherein the DNA taggant is suspended in an aqueous solution or a non-aqueous solution.
  • 7. The method according to claim 1, wherein the ratio of DNA taggant to marker is about 1:100 to about 1:10,000.
  • 8. The method according to claim 7, wherein the ratio of DNA taggant to marker is about 1:800 to about 1:5,000.
  • 9. The method according to claim 1, wherein the DNA security marker further comprises a perturbant.
  • 10. The method according to claim 9, wherein the perturbant comprises a polyol, a diol, a glycol, a starch, or a pyrrolidone.
  • 11. The method according to claim 10, wherein the perturbant is a polyol and the polyol is polyethylene glycol.
  • 12. The method according to claim 9, wherein the DNA taggant is suspended in an aqueous solution and the perturbant is any water immiscible compound capable of creating a stable oil in water emulsion.
  • 13. The method according to claim 12, wherein the perturbant comprises mineral oil, hydrocarbons, silicone oils, or triglycerides.
  • 14. The method according to claim 9, wherein the perturbant is present in the DNA security marker in an amount of less than 2% w/w.
  • 15. The method according to claim 1, wherein the DNA security marker or developer comprises an anion.
  • 16. The method according to claim 1, wherein the DNA security marker or developer comprises a transition metal ion.
  • 17. The method according to claim 16, wherein the transition metal ion comprises Cu2±.
  • 18. The method according to claim 1, further comprising developing the marker with the developer to produce a readily detectable fluorophore, chromophore, or combination thereof.
  • 19. The method according to claim 1, wherein the marker comprises a polymerizable monomer capable of polymerizing to form a solid, a layer, a particle, a microparticle or a nanoparticle.
RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No. 14/661,489, filed on Mar. 18, 2015, now U.S. Pat. No. 10,047,282, which claims the benefit of U.S. Provisional Application Ser. No. 61/954,950, filed on Mar. 18, 2014, the disclosures of which are incorporated by reference herein in their entirety.

US Referenced Citations (220)
Number Name Date Kind
4183989 Tooth Jan 1980 A
4278557 Elwell, Jr. Jul 1981 A
4454171 Diggle, Jr. et al. Jun 1984 A
4548955 Okahata et al. Oct 1985 A
4683195 Mullis et al. Jul 1987 A
4683202 Mullis Jul 1987 A
4736425 Jalon Apr 1988 A
4739044 Stabinsky Apr 1988 A
4757141 Fung et al. Jul 1988 A
4861620 Azuma et al. Aug 1989 A
4965188 Mullis et al. Oct 1990 A
5047519 Hobbs, Jr. et al. Sep 1991 A
5075216 Innis et al. Dec 1991 A
5089691 Morisaki et al. Feb 1992 A
5132242 Cheung Jul 1992 A
5139812 Lebacq Aug 1992 A
5151507 Hobbs, Jr. et al. Sep 1992 A
5156765 Smrt et al. Oct 1992 A
5176203 Larzul Jan 1993 A
5270183 Corbett et al. Dec 1993 A
5415839 Zaun et al. May 1995 A
5429952 Garner et al. Jul 1995 A
5451505 Dollinger Sep 1995 A
5498283 Botros et al. Mar 1996 A
5508197 Hansen et al. Apr 1996 A
5595871 DelVecchio et al. Jan 1997 A
5599578 Butland Feb 1997 A
5602381 Hoshino et al. Feb 1997 A
5639603 Dower et al. Jun 1997 A
5643728 Slater et al. Jul 1997 A
5736314 Hayes et al. Apr 1998 A
5763176 Slater et al. Jun 1998 A
5776713 Garner et al. Jul 1998 A
5849208 Hayes et al. Dec 1998 A
5866336 Nazarenko et al. Feb 1999 A
5912257 Prasad et al. Jun 1999 A
5942444 Rittenburg et al. Aug 1999 A
5956172 Downing Sep 1999 A
5977436 Thomas et al. Nov 1999 A
5989823 Jayasena et al. Nov 1999 A
6013789 Rampal Jan 2000 A
6030657 Butland et al. Feb 2000 A
6033880 Haff et al. Mar 2000 A
6057370 Weiland et al. May 2000 A
6127120 Graham et al. Oct 2000 A
6132996 Hunicke-Smith Oct 2000 A
6140075 Russell et al. Oct 2000 A
6169174 Hasegawa et al. Jan 2001 B1
6261809 Bertling et al. Jul 2001 B1
6287768 Chenchik et al. Sep 2001 B1
6312911 Bancroft et al. Nov 2001 B1
6326489 Church et al. Dec 2001 B1
6342359 Lee et al. Jan 2002 B1
6361944 Mirkin et al. Mar 2002 B1
6379897 Weidenhammer et al. Apr 2002 B1
6399397 Zarling et al. Jun 2002 B1
6537747 Mills, Jr. et al. Mar 2003 B1
6537752 Astle Mar 2003 B1
6576422 Weinstein et al. Jun 2003 B1
6608228 Cumpston et al. Aug 2003 B1
6613560 Tso et al. Sep 2003 B1
6632653 Astle Oct 2003 B1
6686149 Sanchis et al. Feb 2004 B1
6703228 Landers et al. Mar 2004 B1
6709692 Sudor Mar 2004 B2
6743640 Whitten et al. Jun 2004 B2
6995256 Li et al. Feb 2006 B1
7014113 Powell et al. Mar 2006 B1
7015030 Fouillet et al. Mar 2006 B1
7031927 Beck et al. Apr 2006 B1
7060874 Wilkins Jun 2006 B2
7112616 Takizawa et al. Sep 2006 B2
7115301 Sheu et al. Oct 2006 B2
7133726 Atwood et al. Nov 2006 B1
7160996 Cook Jan 2007 B1
7223906 Davis May 2007 B2
7250195 Storey et al. Jul 2007 B1
7709250 Corbett et al. May 2010 B2
7732492 Makino et al. Jun 2010 B2
8278807 Agneray et al. Oct 2012 B2
8597549 Cumpston et al. Dec 2013 B2
9266370 Jung et al. Feb 2016 B2
9297032 Jung et al. Mar 2016 B2
20010039018 Matson et al. Nov 2001 A1
20020048822 Rittenburg et al. Apr 2002 A1
20020051969 Goto et al. May 2002 A1
20020056147 Dau et al. May 2002 A1
20020064639 Rearick et al. May 2002 A1
20020080994 Lofgren et al. Jun 2002 A1
20020119485 Morgan Aug 2002 A1
20020128234 Hubbell et al. Sep 2002 A1
20020129251 Itakura et al. Sep 2002 A1
20020137893 Burton et al. Sep 2002 A1
20020155490 Skinner et al. Oct 2002 A1
20020160360 Chenchik et al. Oct 2002 A1
20020167161 Butland Nov 2002 A1
20020185634 Marder et al. Dec 2002 A1
20020187263 Sheu et al. Dec 2002 A1
20030000225 Nagai et al. Jan 2003 A1
20030017551 Parthasarathy et al. Jan 2003 A1
20030035917 Hyman Feb 2003 A1
20030064507 Gallagher et al. Apr 2003 A1
20030096273 Gagna May 2003 A1
20030142704 Lawandy Jul 2003 A1
20030142713 Lawandy Jul 2003 A1
20030162296 Lawandy Aug 2003 A1
20030177095 Zorab et al. Sep 2003 A1
20030203387 Pelletier Oct 2003 A1
20030207331 Wilson, Jr. et al. Nov 2003 A1
20040063117 Rancien et al. Apr 2004 A1
20040071718 Tsai Apr 2004 A1
20040115796 Burns Jun 2004 A1
20040166520 Connolly Aug 2004 A1
20040219287 Regan et al. Nov 2004 A1
20050008762 Sheu et al. Jan 2005 A1
20050019603 Kathirgamanathan Jan 2005 A1
20050031120 Samid Feb 2005 A1
20050045063 Niggemann et al. Mar 2005 A1
20050053968 Bharadwaj et al. Mar 2005 A1
20050059029 Mariella, Jr. et al. Mar 2005 A1
20050059059 Liang Mar 2005 A1
20050112610 Lee et al. May 2005 A1
20050142565 Samper et al. Jun 2005 A1
20050214532 Kosak et al. Sep 2005 A1
20050260609 Lapidus Nov 2005 A1
20060017957 Degott et al. Jan 2006 A1
20060017959 Downer et al. Jan 2006 A1
20060117465 Willows et al. Jun 2006 A1
20060121181 Sleat et al. Jun 2006 A1
20060199196 O'Banion et al. Sep 2006 A1
20060286569 Bar-Or et al. Dec 2006 A1
20070012784 Mercolino Jan 2007 A1
20070026239 Sigrist et al. Feb 2007 A1
20070048761 Reep et al. Mar 2007 A1
20070072197 Rayms-Keller et al. Mar 2007 A1
20070117119 Akita et al. May 2007 A1
20070121937 Kochevar et al. May 2007 A1
20070254292 Fukasawa et al. Nov 2007 A1
20080038813 Chen Feb 2008 A1
20080081357 Kwon et al. Apr 2008 A1
20080149713 Brundage Jun 2008 A1
20080153135 Liu Jun 2008 A1
20080216255 Poovey et al. Sep 2008 A1
20080248948 Hartlep Oct 2008 A1
20080290649 Klein et al. Nov 2008 A1
20080293052 Liang et al. Nov 2008 A1
20080299559 Kwok et al. Dec 2008 A1
20080299667 Kwok et al. Dec 2008 A1
20080312427 Kwok et al. Dec 2008 A1
20090042191 Hayward et al. Feb 2009 A1
20090057147 Kayyem Mar 2009 A1
20090069199 Brandenburg Mar 2009 A1
20090075261 Hayward et al. Mar 2009 A1
20090136163 Kerr et al. May 2009 A1
20090220789 DeSimone et al. Sep 2009 A1
20090222912 Boschin Sep 2009 A1
20090253127 Gaudreau et al. Oct 2009 A1
20090286250 Hayward et al. Nov 2009 A1
20090311555 Badyal et al. Dec 2009 A1
20090313740 Santos et al. Dec 2009 A1
20090325234 Gregg et al. Dec 2009 A1
20100050344 Peltz et al. Mar 2010 A1
20100065463 Taylor Mar 2010 A1
20100075407 Duffy et al. Mar 2010 A1
20100075858 Davis et al. Mar 2010 A1
20100099080 Church et al. Apr 2010 A1
20100149531 Tang Jun 2010 A1
20100240101 Lieberman et al. Sep 2010 A1
20100250616 Kim Sep 2010 A1
20100258743 Bortolin Oct 2010 A1
20100267091 Murray et al. Oct 2010 A1
20100279282 Liang et al. Nov 2010 A1
20100285447 Walsh et al. Nov 2010 A1
20100285490 Dees et al. Nov 2010 A1
20100285985 Liang et al. Nov 2010 A1
20100307120 Stover Dec 2010 A1
20110054938 Hood et al. Mar 2011 A1
20110165569 Macula Jul 2011 A1
20110229881 Oshima et al. Sep 2011 A1
20110250594 Liang et al. Oct 2011 A1
20110263688 Barany et al. Oct 2011 A1
20120115154 Hampikian May 2012 A1
20120264742 Furuishi et al. Oct 2012 A1
20130040150 Trexler et al. Feb 2013 A1
20130040381 Gregg et al. Feb 2013 A1
20130046994 Shaw Feb 2013 A1
20130048731 Flickner et al. Feb 2013 A1
20130109596 Peterson et al. May 2013 A1
20130149706 Kwok et al. Jun 2013 A1
20130234043 Hussain et al. Sep 2013 A1
20130274129 Katzen et al. Oct 2013 A1
20140099643 Jung et al. Apr 2014 A1
20140106357 Berrada et al. Apr 2014 A1
20140224673 Alocilja Aug 2014 A1
20140256881 Berrada et al. Sep 2014 A1
20140272097 Jung et al. Sep 2014 A1
20140295423 Liang et al. Oct 2014 A1
20150018538 Berrada et al. Jan 2015 A1
20150030545 Grass et al. Jan 2015 A1
20150083797 Tran et al. Mar 2015 A1
20150104800 Lee et al. Apr 2015 A1
20150107475 Jung et al. Apr 2015 A1
20150125949 Liss May 2015 A1
20150133319 Fu et al. May 2015 A1
20150141264 Jung et al. May 2015 A1
20150191799 Liang et al. Jul 2015 A1
20150232952 Sun et al. Aug 2015 A1
20150266332 Szczepanik et al. Sep 2015 A1
20150275271 Berrada et al. Oct 2015 A1
20150302713 Berrada et al. Oct 2015 A1
20150304109 Tran et al. Oct 2015 A1
20150329856 Liang et al. Nov 2015 A1
20160076088 Tran et al. Mar 2016 A1
20160102215 Hayward et al. Apr 2016 A1
20160168781 Tran et al. Jun 2016 A1
20160246892 Murrah et al. Aug 2016 A1
20160264687 Tran Sep 2016 A1
20160326511 Berrada et al. Nov 2016 A1
20160362723 Jung et al. Dec 2016 A1
20170021611 Jung et al. Jan 2017 A1
Foreign Referenced Citations (59)
Number Date Country
2518871 Nov 1975 DE
4443660 Oct 1995 DE
0623658 Nov 1994 EP
0477220 Sep 1996 EP
0840350 May 1998 EP
1063286 Dec 2000 EP
1231470 Aug 2002 EP
1237327 Sep 2002 EP
1403333 Mar 2004 EP
1847316 Oct 2007 EP
2428925 Mar 2012 EP
2444136 Apr 2012 EP
2444546 Apr 2012 EP
2319337 May 1998 GB
2434570 Aug 2007 GB
63-503242 Nov 1988 JP
2009517250 Apr 2009 JP
2084535 Jul 1997 RU
2170084 Jul 2001 RU
8706383 Oct 1987 WO
9014441 Nov 1990 WO
9204469 Mar 1992 WO
9502702 Jan 1995 WO
9506249 Mar 1995 WO
9704392 Feb 1997 WO
9745539 Dec 1997 WO
9806084 Feb 1998 WO
9816313 Apr 1998 WO
9945514 Sep 1999 WO
9959011 Nov 1999 WO
0055609 Sep 2000 WO
0061799 Oct 2000 WO
0125002 Apr 2001 WO
0136676 May 2001 WO
0199063 Dec 2001 WO
02057548 Jul 2002 WO
02066678 Aug 2002 WO
02084617 Oct 2002 WO
03016558 Feb 2003 WO
03030129 Apr 2003 WO
03038000 May 2003 WO
03080931 Oct 2003 WO
2004025562 Mar 2004 WO
2004086323 Oct 2004 WO
WO2004087430 Oct 2004 WO
2005075683 Aug 2005 WO
2005103226 Nov 2005 WO
WO2005108103 Nov 2005 WO
2006109014 Oct 2006 WO
WO2007037586 Apr 2007 WO
2007078833 Jul 2007 WO
2008007060 Jan 2008 WO
2008045288 Apr 2008 WO
2008154931 Dec 2008 WO
2012076021 Jun 2012 WO
2013052924 Apr 2013 WO
2013154943 Oct 2013 WO
2013170009 Nov 2013 WO
2014062754 Apr 2014 WO
Non-Patent Literature Citations (54)
Entry
Kim, Jeong AH et al., “Fabrication and Characterization of a PDMS-Glass Hybrid Continuous-Flow PCR Chip”, Biochemical Engineering Journal, 29, 91-97 (2006).
Curcio, Mario et al., “Continuous Segmented-Flow Poymerase Chain Reaction for High-Throughput Miniaturized DNA Amplification” Analytical Chemistry, vol. 75, No. 1, 1-7 ( Jan. 1, 2003).
Kopp, Martin U. et al, “Chemical Amplification: Continuous-Flow PCR on a Chip”, Science, vol. 280, 1046-1048 (1998).
Skirtach, Andre, G. et al, “The Role of Metal Nanoparticles in Remote Release of Encapsulated Materials”, Nano Letters, vol. 5, No. 7, 1371-1377 (2005).
Fixe, F. et al., Thin Film Micro Arrays with Immobilized DNA for Hybridization Analysis, Mat. Res. Soc. Symp. Proc. vol. 723, Materials Research Society, O2.3.1-O2.3.6 (2002).
Hayward, Jim et al., “A Scaled, Integrative Implementation for DNA Marking of Integrated Circuits”, Applied DNA Sciences, 1-25 (2013).
Ovsianikov, Aleksandr et al., “Two-Photon Polymerization Technique for Microfabrication of CAD-Designed 3D Scaffolds from Commercially Available Photosensitive Materials”, Journal of Tissue Engineering and Regenerative Medicine, 1:443-449 (2007).
Khandjian, E.W., “Optimized Hybridization of DNA Blotted and Fixed to Nitrocellulose and Nylon Membranes” Biotechnology, vol. 5, 165-167 (1987).
Chrisey, Linda A et al., “Fabrication of Patterned DNA Surfaces”, Nucleic Acids Research, vol. 24, No. 15, 3040-3047 (1996).
Wollenberger, Louis V. et al., “Detection of DNA Using Upconverting Phosphor Reporter Probes”, SPIE, vol. 2985, 100-111 (1997).
Takara Bio, “Takara Bio to Produce DNA Fragments for DNA Microarrays on Industrial Scale”, http://www.evaluategroup.com/Universal/View.aspx?type_Story&id.
Obeid, Pierre J. et al., “Microfabricated Device for DNA and RNA Amplification by Continuous-Flow Polymerase Chain Reaction and Reverse Transcription-Polymerase Chain Reaction with Cycle Number Section”, Anal. Chem, 75, 288-295 (2003).
Supplemental European Search Report for Corresponding European Patent Application No. EP14820538.8, pp. 1-8 , (dated Jan. 25, 2017).
Hashimoto, Masahiko et al., “Rapid PCR in a Continuous Flow Device”, Lab Chip, 4, 638-645 (2004).
Thibaudau, Franck, “Ultrafast Photothermal Release of DNA from Gold Nanoparticles”, J. Phys. Chem. Lett. 3, 902-907 (2012).
Berger, S.A. et al., “Flow in Curved Pipes”, Ann. Rev. Fluid Mech., 15:461-512 (1983).
Written Opinion of the International Search Authority for PCT/US2015/013084 dated Apr. 17, 2015.
Ageno, M., et al., “The Alkaline Denaturation of DNA”, Biophys J., Nov. 1969; 9(11): 1281-1311.
Hou, Sen, et al., “Method to Improve DNA Condensation Efficiency by Alkali Treatment”, Taylor & Francis, Nucleosides, Nucleotides and Nucleic Acids, 28:725-735, 2009.
Thiel, Teresa, et al., “New zwitterionic butanesulfonic acids that extend the alkaline range of four families of good buffers: Evaluation for use in biological systems”, J. Biochem. Biophys., Methods 37 (1998) 117-129.
Schulz, M.M., et al., “Archived or directly swabbed latent fingerprints as a DNA source for STR typing”, Forensic Science International 127 (2002) 128-130.
Park, H., et al., “Stress response of fibroblasts adherent to the surface of plasma-treated poly(lactic-co-glycolic acid) nanofiber matrices”, Colloids Surf B Biointerfaces, May 1, 2010,1;77(1); 90-5.
WiseGeek, “How Many Species of Bacteria Are There”, http://www.wisegeek.org/how-many-species-of-bacteria-are-there.htm.
Wikipedia, “List of sequenced bacterial genomes”, http://en.wikipedia.org/wiki/List_of_sequenced_bacterial_genomes.
Wikipedia, “Virus”, http://en.wikipedia.org/wiki/Virus.
Agrawal, Sudhir, et al., “Site-Specific Functionalization of Oligodeoxynucleotides for Non-Radioactive Labelling”, Tetrahedron Letters, vol. 31, No. 11, pp. 1543-1546, 1990.
Beija, Mariana, et al., “Synthesis and applications of Rhodamine derivatives as fluorescent probes”, Chem. Soc. Rev., 2009, 38, 2410-2433.
Corstjens, P.L.A.M., et al., “Infrared up-converting phosphors for bioassays”, IEE Proc.—Nanobiotechnol., vol. 152, No. 2, Apr. 2005.
Tyagi, Sanjay, et al., “Multicolor molecular beacons for allele discrimination”, Nature Biotechnology, vol. 16, Jan. 1996.
Gibson, U.E., et al., “A novel method for real time quantitative RT-PCR”, Genome Res., 1996, 6:995-1001.
Gupta, K.C., et al., “A general method for the synthesis of 3′-sulfhydryl and phosphate group containing oligonucleotides”, Nucleic Acids Research, vol. 19, No. 11, p. 3019-3025 (1991).
Heid, C.A., et al., “Real time quantitative PCR”, Genome Res. 1996 6:986-994.
Holland, Pamela, M., et al., “Detection of specific polymerase chain reaction product by utilizing the 5′→ 3′ exonuclease activity of Thermus aquaticus DNA polymerase”, Proc. Natl. Acad. Sci. USA, vol. 88, pp. 7276-7280, Aug. 1991, Biochemistry.
Hosokawa, Kazuo, et al., “DNA Detection on a Power-free Microchip with Laminar Flow-assisted Dendritic Amplification”, Analytical Sciences, Oct. 2010, vol. 26.
Hussein, Ebtissam, H.A., et al., “Molecular Characterization of Cotton Genotypes Using PCR-based Markers”, Journal of Applied Sciences Research, 3(10): 1156-1169, 2007.
Ibrahim, Rashid Ismael Hag, et al., “Complete Nucleotide Sequence of the Cotton (Gossypium barbadense L.) Chloroplast Genome with a Comparative Analysis of Sequences among 9 Dicot Plants”, Genes Genet. Syst. (2006) 81, p. 311-321.
Jiang, Chun-Xiao, et al., “Polyploid formation created unique avenues for response to selection in Gossypium (cotton)”, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 4419-4424, Apr. 1998.
Kaneda, Shohei, et al., “Modification of the Glass Surface Property in PDMS-Glass Hybrid Microfluidic Devices”, Analytical Sciences, Jan. 2012, vol. 28.
Karahan, H.A., et al., “Improvements of Surface Functionality of Cotton Fibers by Atmospheric Plasma Treatment”, Fibers and Polymers 2008, vol. 9, No. 1, 21-26.
Lee, Seung-Bum, et al., “The complete chloroplast genome sequence of Gossypium hirsutum: organization and phylogenetic relationships to other angiosperms”, BMC Genomics 2006, 7:61.
Lee, Linda G., et al., “Allelic discrimination by nick-translation PCR with fluorogenic probes”, Nucleic Acids Research, 1993, vol. 21, No. 16, 3761-3766.
Tyagi, Sanjay, et al., “Molecular Beacons: Probes that Fluoresce upon Hybridization”, Nature Biotechnology, vol. 18, Mar. 1996.
Sproat, Brian S. et al., “The synthesis of protected 5′ -mercapto-2′, 5′ -dideoxyribonucleoside-3′ -O-phosphoramidites; uses of 5′ -mercapto-oligodeoxyribonucleotides”, Nucleic Acids Research, vol. 15, No. 12, 1987.
Nazarenko, I.A., et al., “A closed tube format for amplification and detection of DNA based on energy transfer”, Nucleic Acids Research, 1997, vol. 25, No. 12, 2516-2521.
Nelson, Paul S., et al., “Bifunctional oligonucleotide probes synthesized using a novel CPG support are able to detect single base pair mutations”, Nucleic Acids Research, vol. 17, No. 18, 1989.
International Preliminary Report on Patentability issued in PCT/US2013/065161 dated Apr. 21, 2015.
Written Opinion of the International Searching Authority issued in PCT/US15/21165 dated Jul. 2, 2015.
Tuzlakoglu, K., et al., “A new route to produce starch-based fiber mesh scaffolds by wet spinning and subsequent surface modification as a way to improve cell attachment and proliferation”, Journal of Biomedical Materials Research Part A, 2009, Wiley Periodicals, Inc, p. 369-377.
Zuckermann, Ronald, et al., “Efficient methods for attachment of thiol specific probes to the 3′ -ends of synthetic oligodeoxyribonucleotides”, Nucleic Acids Research, vol. 15, No. 13, 1987.
Yang, XF, et al., “Fluorimetric determination of hemoglobin using spiro form rhodamine B hydrazide in a micellar medium”, Talanta Nov. 12, 2003; 61(4): 439-45.
Ullrich, Thomas, et al., “Competitive Reporter Monitored Amplification (CMA)—Quantification of Molecular Targets by Real Time Monitoring of Competitive Reporter Hybridization”, Plos One, Apr. 2012, vol. 7, Issue 4.
Van De Rijke, Frans, et al., “Up-converting phosphor reporters for nucleic acid microarrays”, Nature Publishing Group, Nature Biotechnology Mar. 19, 2001, 273-276.
Whitcombe, David, et al., “Detection of PCR products using self-probing amplicons and fluorescence”, Nature Biotechnology, vol. 17, Aug. 1999, p. 804-807.
Hunicke-Smith, Scott P., “PCR and Cycle Sequencing Reactions: A New Device and Engineering Model”, Dissertation, Stanford University, pp. i-xiv and 1-200, May 1997.
Related Publications (1)
Number Date Country
20180312998 A1 Nov 2018 US
Provisional Applications (1)
Number Date Country
61954950 Mar 2014 US
Continuation in Parts (1)
Number Date Country
Parent 14661489 Mar 2015 US
Child 16028176 US